Anti-proliferation Effect of Triptolide-Eluting Stent in Rabbit Models with Iliac Restenosis

王开侠,霍勇,陈明,刘兆平,侯桂华,蔡其渊
DOI: https://doi.org/10.3969/j.issn.1004-8812.2005.03.013
2005-01-01
Abstract:Objective To investigate the anti-proliferation effect of triptolide-eluting stent, as well as its effectiveress, dose-effect relationship and safety. Methods Experimental stents were divided into 4 groups with 10 stents each, namely bare stent group, sirolimus-coated stent group, 5.6 μg triptolide-coated stent group and 56 μg triptolide-coated stent group. By morphometric and histopathologic analysis,we compared 5.6 μg and 56 μg triptolide-eluting stents with bare metal stents and sirolimus-eluting stents 28 days after stenting in rabbit iliac models of restenosis. Results The neointimal area of 5.6 μg triptolide-eluting stents was similar to that of bare metal stents, but larger than that of sirolimus-eluting stents. The neointimal area of 56 μg triptolide-eluting stents was smaller than that of bare metal stents and 5.6 μg triptolide-eluting stents, but was similar to that of sirolimus-eluting stents. In all the groups, proliferation on both edges of the stents was insignificant. No toxic effect had been found in the experimental animals related to triptolide-eluting stent. Conclusion Triptolide-eluting stents may inhibit neointimal proliferation. The effect of inhibiting neointimal proliferation is dose dependent and with no adverse effect. These results suggest that triptolide-eluting stent can prevent restenosis within four weeks.
What problem does this paper attempt to address?